Incidence of Cardiotoxicity Induced by 5-FU and Capecitabine in Colorectal Cancer Patients

Fluoropyrimidines, such as 5-fluorouracil (5-FU) and capecitabine, are standards of care in treating gastrointestinal cancers, breast cancer, and head and neck cancers. However, both 5-FU and capecitabine can potentially induce cardiotoxicity that presents as acute coronary syndromes. A team of researchers led by Anne Dyhl-Polk, PhD of the Department of Oncology at the Herlev-Gentofte Hospital in Copenhagen, Denmark, set out to compare the incidence of cardiotoxicity caused by 5-FU and capecitab...
Continue reading

Has Life Expectancy for Adult Survivors of Childhood Cancer Improved?

Scientists recently discovered that improved cancer treatment approaches over time correlate with higher life expectancy in adult survivors of childhood cancer.As cancer treatment evolves to be more effective, more patients are surviving, with some even living long lives disease free. In order to determine if life expectancy also rises with evolving treatment, the investigators examined data derived from the Childhood Cancer Survivor Study, which included data on 5-year survivors of childhood ca...
Continue reading

Idelalisib: Worse Outcomes in the Clinical Setting vs Clinical Trials

Idelalisib is used as monotherapy to treat relapsed follicular lymphoma (FL) and in conjunction with rituximab for relapsed chronic lymphocytic leukemia (CLL). There is a dearth of data on real-world population outcomes of this therapy. Researchers set out to discover how treatment outcomes of idelalisib for relapsed follicular lymphoma and chronic lymphocytic leukemia in the clinical setting compare with outcomes in clinical trials and found that in the clinical setting, there were less favorab...
Continue reading

Continued Induction, Maintenance, or Observation: Which Is Most Effective for Metastatic Colorectal Cancer?

For patients with metastatic colorectal cancer, the standard treatment is induction combination chemotherapy with a targeted agent. However, clinical trials that involved patients either continuing cytotoxic therapy until disease progression or observation have shown inconsistent efficacy results. To close this gap, a systematic review and network meta-analysis was conducted and revealed that continued induction therapy until progression offered no survival benefit compared with maintenance fluo...
Continue reading

What Are the Most Common Causes of Death for Breast Cancer Survivors?

Researchers discovered that a significant number of breast cancer survivors die from heart and cerebrovascular diseases, providing important insight on how breast cancer survivors should be counseled on potential health risks. In this study, published in Cancer, data on 754,270 women who were diagnosed with breast cancer during 2000 through 2015 from the Surveillance, Epidemiology, and End Results (SEER) program were analyzed. The researchers then calculated standardized mortality ratios for cau...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.